{"title":"Bilateral Pterygium in a Paediatric Cancer Patient Taking Vemurafenib: A Case Report.","authors":"David Choi, Jay J Meyer","doi":"10.1159/000542346","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Anticancer drugs with reactive oxygen species-inducing mechanisms, such as vemurafenib, have been shown to be effective against various types of cancer. However, the adverse effects of increased oxidative stress have the potential to damage not only cancer cells, but also normal cells, potentially leading to ocular diseases such as pterygium and cataract.</p><p><strong>Case presentations: </strong>A 9-year-old patient presented with bilateral nasal pterygia and early bilateral cortical cataracts, which are uncommon for his age group. The patient has a background of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) V600E-positive pilocytic astrocytoma with anaplastic features, diagnosed at age 2.5 years old. Vemurafenib was commenced at the time of diagnosis.</p><p><strong>Conclusion: </strong>We suspect that these ophthalmic findings are associated with his prolonged treatment with vemurafenib which may be of pathophysiological significance.</p>","PeriodicalId":9635,"journal":{"name":"Case Reports in Ophthalmology","volume":"15 1","pages":"841-845"},"PeriodicalIF":0.6000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448670/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000542346","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Anticancer drugs with reactive oxygen species-inducing mechanisms, such as vemurafenib, have been shown to be effective against various types of cancer. However, the adverse effects of increased oxidative stress have the potential to damage not only cancer cells, but also normal cells, potentially leading to ocular diseases such as pterygium and cataract.
Case presentations: A 9-year-old patient presented with bilateral nasal pterygia and early bilateral cortical cataracts, which are uncommon for his age group. The patient has a background of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) V600E-positive pilocytic astrocytoma with anaplastic features, diagnosed at age 2.5 years old. Vemurafenib was commenced at the time of diagnosis.
Conclusion: We suspect that these ophthalmic findings are associated with his prolonged treatment with vemurafenib which may be of pathophysiological significance.
期刊介绍：
This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of ophthalmology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The submission of negative results is strongly encouraged. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information. Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
